Nobelpharma builds commercial ops with Japan fosphenytoin launch
This article was originally published in Scrip
Nobelpharma, a specialist Japanese venture, is continuing to expand its commercial portfolio with the launch in its home market of the anticonvulsant Fostoin (fosphenytoin sodium hydrate), in a move that also marks another small step forward to closing Japan's "drug lag".
You may also be interested in...
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.